Kayel Medichem Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-07-2024
- Paid Up Capital ₹ 5.00 M
as on 26-07-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.80 M
as on 26-07-2024
- Revenue -1.84%
(FY 2023)
- Profit 8.88%
(FY 2023)
- Ebitda 12.46%
(FY 2023)
- Net Worth 16.79%
(FY 2023)
- Total Assets 10.92%
(FY 2023)
About Kayel Medichem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹6.80 M.
Jayesh Chadha, Megha Chadha, Samarth Chadha, and One other member serve as directors at the Company.
- CIN/LLPIN
U74900DL2009PTC188843
- Company No.
188843
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Kayel Medichem Private Limited offer?
Kayel Medichem Private Limited offers a wide range of products and services, including Dyes & Color Additives, White Pigments, Common Disease Medicines, Pharmaceutical Medicine, Pharma Ingredients & Raw Materials, Pharmaceutical Excipients, Flavours & Aromatics, Food Preservative, Food Acidulant, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Kayel Medichem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samarth Chadha  | Director | 25-Mar-2009 | Current |
| Jayesh Chadha | Director | 27-Aug-2018 | Current |
| Megha Chadha | Whole-Time Director | 01-Mar-2013 | Current |
| Manoj Chadha | Director | 25-Mar-2009 | Current |
Financial Performance of Kayel Medichem.
Kayel Medichem Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.84% decrease. The company also saw a slight improvement in profitability, with a 8.88% increase in profit. The company's net worth Soared by an impressive increase of 16.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kayel Medichem?
In 2023, Kayel Medichem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 02 Jul 2021 | ₹5.00 M | Open |
Axis Bank Limited Creation Date: 10 Oct 2019 | ₹1.80 M | Open |
How Many Employees Work at Kayel Medichem?
Unlock and access historical data on people associated with Kayel Medichem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kayel Medichem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kayel Medichem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
